Skip to content
OpenCapital
Get started

Kiniksa Pharmaceuticals International, plc KNSA EV / sales

EV / sales at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
14.1×+3.2×
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
6.8×+2.2×
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
28.8×-15.8×
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
5.8×+1.4×
BridgeBio Pharma logo
BridgeBio PharmaBBIO
28.9×-18.5×
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
2.7×-4.0×

Other financials

Income statement

See full
Revenue$214.3M+55.5%
Gross profit$193.5M+61.3%
Operating income$29.3M+121%
Net income$22.6M+165%
EPS (diluted)$0.27+145%

Balance sheet

See full
Cash & equivalents$190.0M+20.9%
Total debt$9.0M-9.0%
Total equity$605.7M+32.4%
Total assets$825.3M+37.7%

Cash flow

See full
Operating cash flow$50.2M+125%
CapEx$161.0K+62.6%
Free cash flow$50.0M+125%

Valuation

See full
Market cap$4.58B+128%

Profitability

See full
Gross margin89.3%+3.5pp
Operating margin12.4%+10.2pp
Net margin9.7%+7.6pp
FCF margin21.8%+12.2pp

Returns & leverage

See full
Return on equity13.7%+11.3pp
Debt / equity0×0.0×
Current ratio3.8×+0.1×

Where this comes from

Calculated from Kiniksa Pharmaceuticals International, plc’s reported figures.

enterprise value/total revenue=4.6×

Based on the most recent quarter.

The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kiniksa Pharmaceuticals International, plc's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kiniksa Pharmaceuticals International, plc's EV / sales?
Kiniksa Pharmaceuticals International, plc (KNSA) reported EV / sales of 4.6× in Q1 2026.
How has Kiniksa Pharmaceuticals International, plc's EV / sales changed year-over-year?
Kiniksa Pharmaceuticals International, plc's EV / sales increased by 52.5% year-over-year, from 3× to 4.6×.
What is the long-term trend for Kiniksa Pharmaceuticals International, plc's EV / sales?
Over 4 years (2021 to 2025), Kiniksa Pharmaceuticals International, plc's EV / sales has grown at a -29.8% compound annual growth rate (CAGR), from 18× to 4.4×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.